{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T08:31:34Z","timestamp":1788078694312,"version":"build-2784847793"},"reference-count":41,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2009,6,1]],"date-time":"2009-06-01T00:00:00Z","timestamp":1243814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"],"published-print":{"date-parts":[[2009,6]]},"DOI":"10.1016\/j.eimc.2009.04.001","type":"journal-article","created":{"date-parts":[[2009,6,1]],"date-time":"2009-06-01T08:42:36Z","timestamp":1243845756000},"page":"353-362","source":"Crossref","is-referenced-by-count":11,"title":["Antif\u00fangicos para uso sist\u00e9mico"],"prefix":"10.1016","volume":"27","author":[{"given":"Isabel","family":"Ruiz-Camps","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Cuenca-Estrella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eimc.2009.04.001_bib1","first-page":"571","article-title":"[Guidelines for the treatment of infection due to Aspergillus spp]","volume":"21","author":"Gavalda","year":"2003","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.eimc.2009.04.001_bib2","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1157\/13052334","volume":"21","author":"Gavalda","year":"2003","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.eimc.2009.04.001_bib3","first-page":"254","article-title":"[Treatment of invasive fungal infections. 2005. Andalusian Infectious Disease Society.]","volume":"24","author":"Pachon","year":"2006","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.eimc.2009.04.001_bib4","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.2165\/00003495-200868140-00002","article-title":"Patients at high risk of invasive fungal infections: when and how to treat","volume":"68","author":"Ruping","year":"2008","journal-title":"Drugs"},{"key":"10.1016\/j.eimc.2009.04.001_bib5","doi-asserted-by":"crossref","first-page":"3487","DOI":"10.1128\/AAC.45.12.3487-3496.2001","article-title":"Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study","volume":"45","author":"Walsh","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.eimc.2009.04.001_bib6","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1128\/AAC.50.3.917-921.2006","article-title":"Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi","volume":"50","author":"Cuenca-Estrella","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.eimc.2009.04.001_bib7","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s10096-008-0466-x","article-title":"Candida infective endocarditis","volume":"27","author":"Baddley","year":"2008","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.eimc.2009.04.001_bib8","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1086\/317451","article-title":"A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia","volume":"31","author":"Wingard","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2009.04.001_bib9","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1517\/14656566.9.16.2801","article-title":"Pharmacotherapy of yeast infections","volume":"9","author":"Gomez-Lopez","year":"2008","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.eimc.2009.04.001_bib10","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1086\/596757","article-title":"Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America","volume":"48","author":"Pappas","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2009.04.001_bib11","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1086\/525258","article-title":"Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America","volume":"46","author":"Walsh","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2009.04.001_bib12","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1086\/514341","article-title":"Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial)","volume":"44","author":"Cornely","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2009.04.001_bib13","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.healun.2008.11.004","article-title":"Nebulized liposomal amphotericin B prophylaxis for Aspergillus infection in lung transplantation: pharmacokinetics and safety","volume":"28","author":"Monforte","year":"2009","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.eimc.2009.04.001_bib14","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1086\/586739","article-title":"Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial","volume":"46","author":"Rijnders","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2009.04.001_bib15","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1007\/s100960100468","article-title":"Flucytosine primary resistance in Candida species and Cryptococcus neoformans","volume":"20","author":"Cuenca-Estrella","year":"2001","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.eimc.2009.04.001_bib16","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1086\/598327","article-title":"Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents","volume":"48","author":"Bruggemann","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2009.04.001_bib17","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00277-008-0622-5","article-title":"Treatment of invasive fungal infections in cancer patients \u2014recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)","volume":"88","author":"Bohme","year":"2009","journal-title":"Ann Hematol"},{"key":"10.1016\/j.eimc.2009.04.001_bib18","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/S0140-6736(05)67490-9","article-title":"Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial","volume":"366","author":"Kullberg","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.eimc.2009.04.001_bib19","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa020191","article-title":"Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis","volume":"347","author":"Herbrecht","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2009.04.001_bib20","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJM200201243460403","article-title":"Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever","volume":"346","author":"Walsh","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2009.04.001_bib21","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1086\/432579","article-title":"Epidemiology and outcome of zygomycosis: a review of 929 reported cases","volume":"41","author":"Roden","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2009.04.001_bib22","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1128\/AAC.00705-08","article-title":"Antifungal therapeutic drug monitoring: established and emerging indications","volume":"53","author":"Andes","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.eimc.2009.04.001_bib23","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1086\/524669","article-title":"Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes","volume":"46","author":"Pascual","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2009.04.001_bib24","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMoa061094","article-title":"Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia","volume":"356","author":"Cornely","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2009.04.001_bib25","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa061098","article-title":"Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease","volume":"356","author":"Ullmann","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2009.04.001_bib26","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1093\/jac\/dkf045","article-title":"Echinocandins: a new class of antifungal","volume":"49","author":"Denning","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.eimc.2009.04.001_bib27","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1128\/AAC.01543-08","article-title":"Analysis of the activity profile in vitro of micafungin against spanish clinical isolates of common and emerging species of yeasts and moulds","volume":"53","author":"Cuenca-Estrella","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.eimc.2009.04.001_bib28","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/j.1365-2141.2008.07412.x","article-title":"Newer antifungal agents for invasive fungal infections in patients with haematological malignancy","volume":"144","author":"Rogers","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.eimc.2009.04.001_bib29","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa021585","article-title":"Comparison of caspofungin and amphotericin B for invasive candidiasis","volume":"347","author":"Mora-Duarte","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2009.04.001_bib30","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1056\/NEJMoa040446","article-title":"Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia","volume":"351","author":"Walsh","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2009.04.001_bib31","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1542\/peds.2008-1158","article-title":"A prospective, multicenter study of caspofungin for the treatment of documented Candida or Aspergillus infections in pediatric patients","volume":"123","author":"Zaoutis","year":"2009","journal-title":"Pediatrics"},{"key":"10.1016\/j.eimc.2009.04.001_bib32","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1056\/NEJMoa066906","article-title":"Anidulafungin versus fluconazole for invasive candidiasis","volume":"356","author":"Reboli","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2009.04.001_bib33","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1128\/AAC.50.2.632-638.2006","article-title":"Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections","volume":"50","author":"Benjamin","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.eimc.2009.04.001_bib34","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(07)60605-9","article-title":"Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial","volume":"369","author":"Kuse","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.eimc.2009.04.001_bib35","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1097\/INF.0b013e31817275e6","article-title":"Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial","volume":"27","author":"Queiroz-Telles","year":"2008","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.eimc.2009.04.001_bib36","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1093\/jac\/dkh434","article-title":"Combinations of antifungal agents in therapy \u2013what value are they?","volume":"54","author":"Cuenca-Estrella","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.eimc.2009.04.001_bib37","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1086\/374850","article-title":"A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects","volume":"36","author":"Rex","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2009.04.001_bib38","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1128\/AAC.01530-08","article-title":"In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing","volume":"53","author":"Perkhofer","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.eimc.2009.04.001_bib39","doi-asserted-by":"crossref","first-page":"i19","DOI":"10.1093\/jac\/dkm428","article-title":"New and emerging treatments for fungal infections","volume":"61","author":"Pasqualotto","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.eimc.2009.04.001_bib40","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1093\/jac\/dkl525","article-title":"Efficacy of aminocandin in the treatment of immunocompetent mice with haematogenously disseminated fluconazole-resistant candidiasis","volume":"59","author":"Ghannoum","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.eimc.2009.04.001_bib41","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1086\/503428","article-title":"A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis","volume":"42","author":"Pachl","year":"2006","journal-title":"Clin Infect Dis"}],"container-title":["Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213005X09002924?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213005X09002924?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,19]],"date-time":"2018-12-19T06:24:33Z","timestamp":1545200673000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0213005X09002924"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,6]]}},"alternative-id":["S0213005X09002924"],"URL":"https:\/\/doi.org\/10.1016\/j.eimc.2009.04.001","relation":{},"ISSN":["0213-005X"],"issn-type":[{"value":"0213-005X","type":"print"}],"subject":[],"published":{"date-parts":[[2009,6]]}}}